Genetically modified NK-92 cells expressing NKG2D, a key activation receptor of NK cells, have higher anti-tumor activity and CD107 expression (marker for degranulation) than NK-92 cells expressing a CAR T construct (CD28−CD28−CD137-CD3ξ), highlighting the importance of customized signaling molecules in the design of CAR NK cells for optimal NK-cell activation and function [160]. The gene discussed is KLRK1; the disease is neoplasm.